Skip to main navigation

Skip to Content

Menu

About Cerevel
Our Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our Science
- Our scientific strategy
- Our pipeline
Investor & Media
Careers
- Working at Cerevel Therapeutics
- Open positions
Contact Us

News & Announcements

News & Announcements

Year

Dec 17, 2020

The NEWDIGS Initiative at MIT welcomes Cerevel Therapeutics as a new collaborator on the LEAPS Project

Dec 14, 2020

Cerevel Therapeutics to Host Inaugural Virtual R&D Event

Dec 08, 2020

Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors

Dec 04, 2020

Cerevel Therapeutics to Host Investor Webcast Moderated by Stifel

Nov 23, 2020

Cerevel Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

Nov 16, 2020

Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights

Nov 04, 2020

Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences

Oct 30, 2020

Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson’s Disease

Oct 28, 2020

Cerevel Therapeutics Debuts as Publicly Traded Neuroscience Company

Oct 06, 2020

Cerevel Therapeutics Announces First Patient Dosed in Phase 2 Trial of CVL-865, an Investigational Therapy in Development for the Treatment of Epilepsy

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18

Print

RSS Feeds

Email Alerts

Investor Contact

Search

Cerevel

About CerevelAbout Cerevel
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our ScienceOur Science
- Our scientific strategy
- Our pipeline
NewsroomNewsroom
CareersCareers
- Working at Cerevel Therapeutics
- Open Positions
Contact Us

Facebook
Twitter
LinkedIn
YouTube

Cerevel

Terms of Use
Privacy Policy

© 2021 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of

Cerevel Therapeutics. All Rights Reserved.